From month 12 to 24 in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) trial, when treatment was at investigator discretion, what were outcomes among participants initially randomized to aflibercept or bevacizumab for treatment of macular edema due to central retinal or hemiretinal vein occlusion?
Among 236 participants in this secondary analysis of the SCORE2 randomized clinical trial, visual acuity letter score and optical coherence tomography–measured central subfield thickness improvement from baseline to month 12 subsequently worsened from month 12 to 24 in both groups, with no differences between treatment groups.
Management of macular edema due to retinal vein occlusion likely warrants close monitoring for at least 2 years, although follow-up of only two-thirds of participants at month 24 limits confidence in these results.
Two-year outcomes are reported comparing eyes originally assigned to aflibercept or bevacizumab to assess the need for continued anti–vascular endothelial growth factor (VEGF) therapy for macular edema due to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO) from participants in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) trial.
To investigate outcomes 1 year after cessation of the SCORE2 treatment schedule.
Design, Setting, and Participants
In this secondary analysis of the SCORE2 randomized clinical trial, follow-up included 117 participants originally randomized to aflibercept and 119 participants originally randomized to bevacizumab between September 17, 2014, and November 18, 2015. Data for the analyses were frozen on September 13, 2018.
SCORE2 participants completed the treatment protocol at month 12, were subsequently treated at investigator discretion, and underwent assessment at month 24.
Main Outcomes and Measures
Visual acuity letter score (VALS) and central subfield thickness (CST) on spectral-domain optical coherence tomography.
Among 362 participants randomized to aflibercept or bevacizumab, 65.2% (236 of 362) completed a protocol visit at month 24 (mean [SD] age, 68.5 (12.0) years; 53.8% male). The mean (SD) VALS improved from baseline to 12 months by 21.6 (14.5) in the aflibercept group compared with 21.9 (16.6) in the bevacizumab group (difference, −0.3; 99% CI, −5.6 to 4.9), then worsened from those values by a mean (SD) VALS of 7.6 (17.5) in the aflibercept group and 7.5 (14.5) in the bevacizumab group (difference, −0.1; 99% CI, −5.6 to 5.3) at month 24. The mean (SD) CST improved from baseline to 12 months by 394 (231) μm in the aflibercept group compared with 420 (274) μm in the bevacizumab group (difference, 26 μm; 99% CI, −62 to 114 μm), then worsened from those values by a mean (SD) of 58 (192) μm in the aflibercept group compared with 48 (186) μm in the bevacizumab group (difference, 10 μm; 99% CI, −58 to 78 μm) at month 24.
Conclusions and Relevance
No differences in VALS or CST outcomes at month 24 were identified when participants originally assigned to aflibercept were compared with those assigned to bevacizumab. Caution in interpretation is needed because of loss to follow-up. In both groups, VALS and CST improved through month 12 and then worsened somewhat during the second year, when treatment was at investigator discretion. This analysis suggests that CRVO and HRVO warrant close monitoring and treatment as needed over at least 2 years to optimize outcomes in eyes treated with anti-VEGF therapy.
ClinicalTrials.gov identifier: NCT01969708
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Scott IU, Oden NL, VanVeldhuisen PC, et al. Month 24 Outcomes After Treatment Initiation With Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion: SCORE2 Report 10: A Secondary Analysis of the SCORE2 Randomized Clinical Trial. JAMA Ophthalmol. Published online October 10, 2019. doi:10.1001/jamaophthalmol.2019.3947
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: